photo walkheader_zpsd5bunpmi.png

Category Archives: Pancreatic Cancer

Lack of Pancreatic Cancer Radiologic Improvement May NOT be an Accurate Measure of Neoadjuvant Success – an important and intriguing finding.

Researchers from the University of Texas / MD Anderson Cancer Center published an interesting recent study in the journal Cancer on the treatment and assessment of so-called neoadjuvant therapy in borderline resectable pancreatic cancer (ductal adenocarcinoma of the pancreas). “Neoadjuvant” is a word that denotes typically the medical and/or radiological treatment of pancreatic cancer BEFORE […]

DNA Marker Differences in Asians vs. Europeans with Pancreatic Cancer

Canzian and estimable European colleagues including Dr. John Neoptolemos of Liverpool University (and again our Professor Markus Buchler of the University of Heidelberg / Pancreatica Science Board)  in a February 2013 article in the Cancer Epidemiology, Biomarkers, and Prevention – a publication of the American Association for Cancer Research through their newly formed collaborative called […]

Evaluating the Xeloda and Tarceva Oral Regimen for Advanced Pancreatic Cancer

Spanish research Fulgar and colleagues published a recent article in the journal Anticancer Research detailing the results of their multi-center Phase 2 clinical trial evaluating oral erlotinib (Tarceva – 150 mg per day) coupled with the also orally administered capecitabine (Xeloda) in pancreatic cancer (ductal adenocarcinoma of the pancreas).  Capecitabine is a pro-drug of 5-FU […]

Page 30 of 37« First...1020...2829303132...Last »